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Prophylactic central neck dissection (pCND) in diﬀerentiated thyroid carcinoma (DTC) is one of the most controversial surgical
subjects in recent times. To date, there is little evidence to support the practice of pCND in patients with DTC undergoing total
thyroidectomy. Although the recently revised American Thyroid Association (ATA) guideline has clarified many inconsistencies
regarding pCND and has recommended pCND in “high-risk” patients, many issues and controversies surrounding the subject of
pCND in DTC remain. The recent literature has revealed an insignificant trend toward lower recurrence rate in patients with DTC
who undergo total thyroidectomy and pCND than those who undergo total thyroidectomy alone. However, this was subjected to
biases, and there are concerns whether pCND should be performed by all surgeons whomanage DTC because of increased surgical
morbodity. Performing a unilateral pCND may be better than a bilateral pCND given its lower surgical morbidity. Further studies
in this controversial subject are much needed.
1. Introduction
Diﬀerentiated thyroid carcinoma (DTC) accounts for over
90% of all follicular cell-derived thyroid malignancies and
is the commonest primary endocrine-related malignancy. In
our locality, its age-adjusted incidence has doubled over the
last 25 years, and a similar trend has been observed elsewhere
[1]. Despite this, the cancer-specific mortality remains low
with an overall 10-year survival above 90% [2]. However,
recurrent/persistent disease after seemingly curative surgery
remains a major cause of patient morbidity and poses a
management challenge for clinicians [3, 4]. Furthermore,
clinicians have witnessed a paradigm shift in the definition
of cure from not dying of the disease to being “completely
disease-free” with good quality of life and to, more recently,
having undetectable postsurgical stimulated thyroglobulin
(Tg) levels [5–8]. However, despite our best eﬀort, overall
15 to 30% of patients with DTC develop locoregional recur-
rences after successful initial operation leading to increased
patient morbidity. Numerous studies have shown that these
recurrences most commonly involve the locoregional lymph
nodes [3, 4, 9]. In terms of lymph node metastases, at
the time of first presentation, up to 20–30% patients with
PTC would have gross involvement and approximately 90%
would have microscopic involvement (i.e., micrometastases)
[7, 10]. Therefore, lymph node metastases in PTC is very
common, but it is only over the last 10–15 years that lymph
node metastasis is recognized to be associated with a poorer
cancer-specific survival [7, 11–15]. With better understand-
ing of the lymphatic drainage of the thyroid gland, it is now
believed that lymphatic metastasis of DTC tends to occur
in the ipsilateral central compartment as the first place for
metastasis. From there, it next spreads either to the ipsilateral
lateral compartment or contralateral central compartment
[16–18]. In attempt to further improve the management
of lymph node metastases, the role of prophylactic central
neck dissection (pCND) has been extensively studied over
the past 5–10 years. For surgeons, pCND has become one of
2 Journal of Oncology
the major research focuses. In year 2006, American Thyroid
Association (ATA) published a guideline on management
of thyroid cancer and suggested that “pCND should be
considered for patients with papillary thyroid cancer” [19].
This recommendation was based on the association between
lymph node metastasis, recurrence, and survival. It was
also based on the assumption that pCND would reduce
the risk of recurrence and perhaps improve cancer-specific
survival. However, this recommendation was criticized as
being vague and imprecise, and it also generated much
controversy among the surgical community. In the revised
guideline by ATA in 2009, they recommended a much more
risk-orientated approach and suggested that “pCND may
be performed, especially in patients with advanced primary
tumors” and “total thyroidectomy without prophylactic
central neck dissection may be appropriated for small (T1 or
T2), non-invasive, clinically node negative patients [7].”With
changes in attitude on pCND over recent years, the authors
believe it is timely to examine the role of pCND at the time
of thyroidectomy in patients with DTC. In the present review,
the authors would focus on the potential benefits and mor-
bidities of pCND and examine some of the arguments for
and against pCND and its implication on future treatment.
2. Definition of a Central Neck
Dissection (CND)
Despite numerous reports describing the technique of per-
forming a CND, there were inconsistencies regarding the
definition of what is a CND and what constitute the central
neck compartment [17, 18, 20, 21]. An example of this incon-
sistency would be the definition of the upper extent of CND.
Some surgeons would describe it as inferior thyroidal artery
[20, 22], while others would describe it as superior thyroid
artery [23] or more commonly hyoid bone [24–28]. Fur-
thermore, as a result of these inconsistent descriptions and
terminologies on CND, at times, it is diﬃcult to assess the
results on CND in diﬀerent studies. With the contribution
of experts from endocrinology, endocrine surgery, otolaryn-
gology, head and neck surgery, and radiology, the working
group within the ATA published a guideline focusing on rel-
evant anatomy and nodal subgroups of central compartment
and defining a consistent terminology to facilitate consistent
reporting on operation records and publications [29].
In the recent ATA guideline, the central neck compart-
ment is described as bounded by hyoid bone (superiorly),
carotid arteries (laterally), superficial layer of deep cervical
fascia (anteriorly), and deep layer of deep cervical fascia
(posteriorly). It is also referred as level VI if inferior
boundary was defined as sternal notch, although, in the
literature, the term “central neck compartment” and “level
VI” have been used interchangeably [30, 31]. In thyroid
gland, lymphatic vessels communicate with anterior superior
mediastinum, which can be accessible by cervical approach,
ultimately to thoracic duct. To achieve adequate lymphatic
excision, inferior border of central compartment is defined
by the innominate artery on the right and corresponding
level on left. However, some would refer this area as level
VII [30] (Figure 1). In terms of nodal groups, they include
IIB
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Figure 1: Schematic right anterior oblique view indication levels of
the neck and upper mediastinum relevant to neck dissection [29]
(reproduced with permission).
prelaryngeal (Delphian), pretracheal, and at least one para-
tracheal lymph nodal basin. Either unilateral or bilateral
paratracheal central neck dissection could be performed
and designated in the operation record. Comprehensive
compartmental neck dissection does not include “berry-
pricking” or limited neck dissection as they are usually
associated with higher rate of recurrence [32, 33].
ATA working group also developed a consensus on
terminology on intention of central neck dissection. A CND
can either be therapeutic (i.e., nodal metastasis detected
clinically or radiologically before or during operation) or
prophylactic (nodal metastasis was not detected clinically
or radiologically). This is an important distinction because
few, if any, surgeons would disagree on performing a CND
if it was done for a therapeutic intent whereas the major
controversy remains in the prophylactic intent. According
to the recent recommendation, apart from stating the
intent, a description of unilateral (removal of prelaryngeal,
pretracheal, and one paratracheal nodal basin) or bilateral
(removal of prelaryngeal, pretracheal, and both paratracheal
nodal basin) CND should be clearly documented. With
standardization on description of indication and extent
of neck dissection, communication between health care
workers should improve and that serves as a good foundation
for future clinical studies.
3. Arguments for pCND in DTC
Table 1 summarizes some of the arguments for pCND in
DTC. One of the arguments for pCND is that central lymph
node metastasis is very common and may have certain
prognostic significance. As mentioned earlier, gross lymph
node metastasis is present in up to 20–50% of the patients
with standard pathological techniques and micrometastasis
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Table 1: A summary of the arguments for and against prophylactic neck dissection (pCND) during total thyroidectomy for diﬀerentiated
thyroid carcinoma.
Arguments for pCND Arguments against pCND
Subclinical central lymph node metastasis
is common
Only a small proportion of subclinical central lymph node
metastasis would develop clinically significant recurrences
Lymph node metastasis leads to higher recurrences and
poorer survival
There is no level-one evidence to suggest that pCND could improve
survival
pCND may reduce recurrence and lower postoperative
thyroglobulin levels
Tumor upstaging leads to more radio-iodine ablation which might
not be necessary
Preoperative and intraoperative evaluations of central
compartment lymph node metastasis are not reliable
Operation in recurrent case could be safely performed by experience
hands
Improved tumor staging and stratification of tumors Majority of thyroidectomy are performed by low-volume surgeons
Reduce the need for reoperation in central neck
recurrence which is associated with greater morbidity
Increased surgical morbidities (hypoparathyroidism and recurrent
laryngeal nerve injury)
pCND can be safely performed with comparable
morbidity to thyroidectomy alone in experience hands
is present in 90% of lymph nodes [10, 19]. Up to 15 to 30% of
patients with PTC would develop recurrence after successful
thyroidectomy secondary to lymph node metastasis [3, 4,
9]. Earlier studies suggested that there was an association
between presence of lymph node metastasis and local
recurrence but not cancer-specific mortality [34]. Wada et
al. reported a study of 134 patients and showed that patients
with lymph node metastasis had a significantly higher rate of
recurrence (16.3% versus 0%, P < 0.05). Clinically apparent
lymph node in addition was more prone to have recurrence
(24% versus 7.6%) [35]. This finding is supported by other
studies [36]. A case series with longer follow-up period
similarly reported lymph node metastasis at presentation
associated with increased risk of recurrence but not cancer-
specific mortality [37]. Various risk stratification systems
assessing survival such as MACIS [38], AGES [39], and
AMES [40] have deliberately left out lymph node metastasis
as a parameter. As a result, the importance of lymph node
metastasis aﬀecting survival was underemphasized in the
earlier period. However, more recent large-scale studies
suggested that lymph node metastasis may have a negative
eﬀect on survival. Mazzaferri and Jhiang reported a study
of 1300 patients with 30 years of followup and found that
lymph node metastasis was associated with increased cancer-
specific mortality in 20-year time (10% versus 6%) [13].
According to Surveillance Epidemiology and End Results
database comprising 19,918 patients, there was a significant
but small diﬀerence in survival between patient with or
without lymph node metastasis [14]. For patients with
lymph node metastasis, the 14-year survival rate was 79%
and 82% in nonmetastatic patients (P < 0.05) [14]. Another
large population-based case control study with 5123 patients
over a 30-year period shows 595 patients who died of thyroid
cancer [15]. Predictors for cancer-related deaths included
distant metastasis (odd ratio (OR) 6.6, 95% confidence
interval (CI) 4.1–10.5), incomplete resection (OR 4.2, 95%
CI 3.1–5.6), and lymph node metastasis (OR 1.9, 95%
CI 1.1–3.6) [15]. Presence of nodal metastasis was also
correlated to persistence and recurrence of PTC [11, 12].
The second argument for pCND is that central lymph
node metastasis cannot be reliably diagnosed preoperatively,
especially when the thyroid gland has not been removed.
Although the use of ultrasound is now regarded as a standard
preoperative workup modality in DTC, detection of central
neck lymph node metastasis with preoperative ultrasound
examination remains diﬃcult [41]. Preoperative ultrasound
in detection of lymph node metastasis has a high specificity
(92%) and positive predictive value (81–92.1%), but low
sensitivity (51–61%) and negative predictive value (63.4–
76%) [42, 43]. And it is not sensitive to detect central
compartment metastasis with ultrasound (sensitivity of
30.0% versus sensitivity of 93.8% in lateral neck metastasis)
[44]. Because of the inaccuracy of preoperative ultrasound,
pCND has been advocated. The reasons for this inaccuracy
include, firstly, these abnormal central lymph nodes are often
small in size [45] and, secondly, the location of these lymph
nodes is often deep down in the neck just posterior to the
sternum making the ultrasound beam diﬃcult to reach [44].
The third argument is that those without pCND are
at higher risk of central neck recurrence and central neck
reoperation is associated with a higher morbidity than
pCND when done at the time of initial total thyroidectomy.
With more frequent and sensitive surveillance modalities
available (e.g., stimulated Tg levels), earlier local recurrence
or metastasis is now being able to be diagnosed. Despite its
unknown and somewhat controversial clinical significance,
reoperation over level VI lymph node and thyroid bed near
tracheoesophageal groove is often advocated because of fear
for further local invasion (e.g., to recurrent laryngeal nerve)
and distant metastasis. But it is associated with significantly
increased morbidity in the reoperative setting [46]. Sec-
ondary to scar tissue and distortion of anatomy, recurrent
laryngeal nerves and parathyroid glands are generally more
diﬃcult to be identified [47, 48]. In a small series, in up
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to 15% of cases, the recurrent laryngeal nerve failed to be
located intraoperatively and that resulted in unintentional
nerve injury [49]. Segal et al. reported a retrospective review
of 503 patients and showed a higher rate of permanent
recurrent nerve injury (5.8% versus 25%) and permanent
hypoparathyroidism (5.0% versus 8.3%) in reoperation
compared with primary operation [50]. Beside recurrent
laryngeal nerve, parathyroid gland was also at risk. Other
studies found similar findings [18, 51–53]. Devascularization
of glands and accidental removal of parathyroid gland occur
commonly in central neck reoperation because it is diﬃcult
to diﬀerentiate a metastatic lymph node from a parathyroid
gland and there is a tendency of more extensive dissection in
recurrent cases [47, 54]. With pCND performed in the initial
operation, it obviates the need or at least reduces the chance
of returning to the operated field. Therefore, initial pCND
may avoid the significant morbidity associated with central
neck reoperation.
4. Argument against pCND in DTC
Table 1 lists some of the arguments against pCND in
DTC. Firstly, in a true prophylactic setting, only small
and subclinical metastatic lymph nodes would be identified
at the time of operation [55]. One study has found that
most of these involved lymph nodes were subclinical and
≤5mm in size (66%) [56]. For most surgeons, it is diﬃcult
to believe that they would ultimately result in significant
poor prognosis as macroscopic metastasis in the therapeutic
setting would. Furthermore, as reported previously, micro-
scopic metastasis is present in central compartment in up
to 63% [6], but the recurrence rate remains acceptably low
in this situation (1.3–6%) [3, 28]. Although there is no
strict definition of defining micrometastasis, it seems that
there is a real diﬀerence between presence of microscopic
metastasis and macrometastasis on future recurrence. This
was somewhat confirmed by a few studies, mostly from
Japan. Wada et al. reported their study on 259 patients with
papillary microcarcinoma of thyroid about their recurrence
with 53-months (mean) followup. For patients undergoing
therapeutic neck dissection, the recurrence rate was 21%.
While only 0.43% patient undergoing pCND developed
recurrence despite high microscopic lymph node involve-
ment rate (61%) [57]. In addition, in a subgroup of patients
without clinically or radiologically overt metastasis that has
not undergone a central neck dissection, the locoregional
recurrence rate was acceptably very low (0.65%) [57].
Gemseja¨ger et al. reported a consistent and similar finding
on their study of 159 patients with papillary thyroid cancer
in 2003 [58]. After mean follow up of 8.1 years, central
neck recurrence rate was 7.1% and 0% in patient with
therapeutic and pCND, respectively. For patients indicted
but not having pCND, the recurrence rate was also 0%
[58]. Furthermore, it is now believed that most of these
micrometastases are expected to be controlled or ablated
by radioiodine (RAI) ablation under thyroid stimulating
hormone stimulation [8]. For patients harboring central
neck compartment micrometastasis, pCND dissection only
provides a small benefit in terms of recurrence, especially
in those with papillary microcarcinoma and the overall
prognosis might not change after removal of nonpalpable
microscopic metastatic lymph nodes [5, 23, 57].
Some authors are concerned that pCND would be widely
adopted when its eﬃcacy has been confirmed [55]. The
potential benefits of pCND should be balanced against the
possible increased morbidity. Some have questioned on the
applicability of pCND in the wider surgical community as
not all surgeons would have same surgical experience. Low
morbidity rate in pCND was reported while the operation
was done by experienced surgeons [6, 8, 23]. However,
more than half of the operations on patients undergoing
thyroidectomy were performed by surgeons who performed
less than 5 cases per year in US [59]. Like other types
of surgery, the rate of complications is inversely related to
the volume of surgery done in that particular center or
by that particular surgeon [60, 61]. Therefore, the surgical
morbidity is expected to be significantly higher in low-
volume surgeons. Another point worth noting is the fact that
although central neck reoperation might be associated with
higher morbidity than initial pCND, Shen et al. has argued
that in “experienced” hands, a central neck reoperation could
also be performed as safely as a nonreoperated CND [47].
5. A Literature Review of Survival Outcomes
and Morbidities of pCND in DTC
To date, there is little good evidence to show that pCND
improves cancer-specific survivals in DTC. Table 2 shows a
literature summary of studies which specifically evaluated
cancer-specific survival between thyroidectomy alone or
thyroidectomy with pCND. To date, the strongest evidence
supporting the role of pCND in DTC came from an earlier
study carried out by a Swedish group. Tisell et al. [28]
evaluated 175 patients who underwent thyroidectomy with
CND and compared with contemporaneous controls from
other two studies of Scandinavian population conducted
on patients in Norway and Finland [62, 63]. They showed
that patients who underwent thyroidectomy with pCND had
a higher survival rate (1.6% versus 8.4–11.1%). However,
these studies were criticized for their lack of no statistical
comparison between two diﬀerent study periods (Swedish:
1970–1989 [28]; Finland: 1956–1979; Norway: 1970–1989)
and for their diﬀerence in rate of curative surgery [62–64].
Another important outcome parameter or survival sur-
rogate is disease recurrence or disease-free survival. Table 3
shows a literature summary of studies which evaluated
recurrences between thyroidectomy alone or thyroidectomy
with pCND. There have been great variations in terms of
indication (therapeutic or prophylactic), extent (unilateral
or bilateral), and duration of followup among diﬀerent
studies. The majority of studies did not show any significant
diﬀerences. Moo et al. reported a decrease in recurrence rate
in patients who underwent bilateral pCND (4.4% versus
16.7%P = 0.13) [24]. Zungia and Sanabria analyzed a
cohort of 266 patients with 6.3 years mean followup and
reported the 5-year disease-free survival was comparable
(88.2% versus 85.6%; P = 0.72) [65]. Interestingly, a
recent meta-analysis comprising 5 retrospective comparative
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Table 2: A comparison of cancer-specific mortality between those who underwent a total thyroidectomy and prophylactic neck dissection
(CND+ group) and those who underwent a total thyroidectomy only (CND− group).
First
author/year
Number of patients
Followup duration
(months)
Cancer-specific
mortality
P value First author/year Number of patients
CND+ group CND− group CND+ group CND− group
Tisell/1996 [28] 195
199 [62];
167 [63]
156 months
(median)
1.6% 8.4%–11.1% Not reported
Sywak/2006 [5] P-56, A 391
CND−: 70 months;
CND+: 25 months
(median)
0% 0% Not significant
Roh/2007 [23]
P-40, B
T-42 (26/42 with lateral
neck dissection)
73
52 months
(mean)
0% 0% Not significant
CND−: thyroidectomy alone, CND+: thyroidectomy plus central neck dissection; P: prophylactic, T: therapeutic; A: unilateral, B: bilateral.
Table 3: A comparison of recurrence rates between those who underwent a total thyroidectomy and prophylactic neck dissection (CND+
group) and those who underwent a total thyroidectomy only (CND− group).
Study design First author/year
Number of patients
Followup (mean)
Overall recurrence P value
CND+ group CND− group CND+ group CND− group
Retrospective
Gemsenja¨ger/2003
[58]
P-29 88 8.1 years 3.4% 2.3% Not mentioned
Retrospective Wada/2003 [57] P-235 155 53 months 0.4% 0.6% Not significant
Retrospective Sywak/2006 [5] P-56, A 391
CND−: 70 months
CND+: 24.5 months
(median)
3.6% 5.6% Not mentioned
Retrospective Roh/2007 [23]
P-40, B
T-42, B
73 52 months
P-0%
T-1.2%
4.0% Not mentioned
Retrospective Zungia/2009 [65] P-136,B 130 6.9 years
5 yr
DFS-88.2%
5 yr
DFS-85.6%
0.72
Retrospective Costa/2009 [67] P-126, B 118
CND−: 64 months
CND+: 47 months
6.3% 7.7% 0.83
Retrospective Moo/2010 [24] P-45, B 36 3.1 years 4.4% 16.7% 0.13
Meta-analysis Zetoune/2010 [66] P-396, A/B 868 2.0% 3.9% NS
Retrospective Lang/2011 [8] P-82, A 103 26 months (median) 3.7% 2.9% 1.0
P: prophylactic, T: therapeutic; A: unilateral, B: bilateral; 5 yr DFS: 5-year disease-free survival.
studies (n = 1264) found that there was an insignificant
trend toward lower overall recurrence rate in the group
who underwent either unilateral or bilateral pCND when
compared to those who had total thyroidectomy only (2.02%
versus 3.92%, odds ratio = 1.05, 95%CI = 0.48−2.31) [66].
Their subgroup analysis revealed no decrease in central
(1.86% versus 1.68%, OR 1.31, 95% CI 0.44–3.91) or lateral
compartment recurrence (3.73% versus 3.79%, OR 1.21,
95% CI 0.52–2.75) [66]. Therefore, based on these findings,
theremight be a potential benefit of lower recurrence in those
who underwent either unilateral or bilateral pCND, although
larger-scale prospective studies are required to confirm
this.
Serum Tg level is useful in detecting persistent or
recurrent DTC after thyroidectomy and RAI ablation [9].
A detectable postsurgical Tg level is associated with risk of
recurrence, and so it may be applied as an surrogate marker
of outcome in studying prognosis of DTC [7, 12]. Sywak
et al. examined 447 patients with clinically node-negative
papillary thyroid carcinoma, while 56 patients underwent
thyroidectomy plus pCND [5]. Though there was no signifi-
cant diﬀerence in recurrence or survival after a short-median
followup (thyroidectomy plus central neck dissection versus
thyroidectomy alone: 25 versus 70 months), they showed
that there was a significantly lower level of stimulated Tg
at 6 months after RAI ablation (mean: 0.41 versus 9.3, P =
0.02) and higher proportion of athyroglobulinemia (72%
versus 43%; P < 0.001) [5]. In contrast, Hughes et al.
found that there was no diﬀerence in postablation median-
stimulated Tg level or rate of athyroglobulinemia between
patients undergoing thyroidectomy with or without bilateral
pCND [6]. However, in their subgroup analysis of patient
undergoing central neck dissection, they demonstrated that
preablation Tg level was significantly higher in node-
positive patient, these patients achieved a comparable rate
of postablation athyroglobulinemia after a higher dose of
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RAI [6]. More recently, Lang et al. retrospectively analyzed
185 patients with PTC and of these, 82 (44.3%) patients
had an unilateral pCND together with a total thyroidectomy
(CND+ group) [8]. They found that the CND+ group had
a significantly lower median preablative-stimulated Tg level
(<0.5 ug/L versus 6.7 ug/L, P < 0.001) and achieved a higher
rate of preablative athyroglobulinemia (51.2% versus 22.3%,
P = 0.024) than those who underwent a total thyroidectomy
only, but these diﬀerences were not observed 6 months
after ablation. They also found that pCND was the only
independent factor for preablative athyroglobulinemia [8].
In their experience, most of the residual microscopic disease,
presumably not removed by the initial pCND, was still able
to be ablated by RAI ablation, and so the group without
pCND achieved similar stimulated Tg levels and similar
rate of athyroglobulinemia 6 months after ablation [8]. The
authors concluded that although performing pCND in total
thyroidectomy may oﬀer a more complete initial tumor
resection than total thyroidectomy alone by minimizing any
residual microscopic disease, such diﬀerence becomes less
noticeable 6 months after RAI ablation [8].
Increased patient morbidity is one of the major concerns.
Increased risk of transient hypoparathyroidism has been
consistently shown in many studies [5, 6, 8, 22–24, 27].
Table 4 shows a comparison of patient morbidities between
CND+ and CND− groups. The higher rate of temporary
hypoparathyroidism could be explained by the higher rate of
unintentional removal of parathyroid glands (i.e., uninten-
tional parathyroidectomy) and subsequent autotransplanta-
tion [5, 6, 8]. Unintentional devascularization of parathyroid
glands during dissection also contributes to the higher rate
of temporary hypoparathyroidism. In terms of temporary
recurrent laryngeal nerve injury, Palestini et al. reported
a higher rate transient recurrent laryngeal nerve injury
in patients undergoing thyroidectomy plus bilateral neck
dissection (1.4% versus 5.4%, P < 0.05) [22], while other
studies failed to show any statistically significant diﬀerences
[5, 6, 8, 23, 25, 27]. To date, no studies have shown an
increase risk of permanent hypoparathyroidism or recurrent
laryngeal nerve injury. A recent systematic review comprising
5 retrospective studies evaluated the morbidity of pCND and
found that there was one extra case of transient hypocal-
caemia for every eight pCNDs performed [68]. However,
there was no increased risk of permanent hypocalcaemia,
transient or permanent recurrent nerve injury [68].
6. Implications on Overall DTC Treatment
Even though it is generally agreed that large-sized DTC,
extrathyroidal extension, or lymph node metastasis would
benefit from postsurgical radio-iodine ablation, the decision
for RAI ablation in DTC less than 2 cm in diameter remains
less clear and it mostly depends on the lymph node status
[7]. pCND could provide more accurate pathological staging
because of better known central compartment lymph node
status (i.e., N0 or N1a instead of Nx) and also more frequent
administration of RAI ablation because of greater incidence
of N1a. From previous studies, up to 30% of DTCs were
upstaged as a result of pCND [6, 8, 26]. Even in the absence of
extrathyroidal extension or other prognostic factors, pCND
aﬀects the final tumor stages of patients aged over 45 years
old because tumors are upstaged from stage I/II to III based
on the stage groupings in the AJCC/UICC TNM staging
system [71, 72]. In terms of survival, they would be classified
as stage III with 10-year survival close to 85–90% while
those patients younger than 45 would still remain as stage
I with 10-year survival rates of more than 95% [2, 73]. This
obvious stage migration is an issue which surgeons should be
aware of. On the long run, this may translate into an overall
improvement in cancer-specific survival, particularly tumors
belonging to stages I-III, because similar risk DTCs are being
upstaged [72].
For low-risk patients, RAI ablation at best only provide
minimal benefits in terms of recurrence or survival [7].
Ross et al., in retrospective analysis of 611 patients with
papillary microcarcinoma, found that RAI ablation did not
reduce recurrence rate in patients with nodal metastasis
(17% versus 11%) [74]. Hay reported a series of 1000 patients
on use of RAI and also found that RAI had no eﬀect on
recurrence or mortality in patients with MACIS score <6
[75]. After pCND, application of RAI in view of upstaged
status might not provide additional benefit in this low-
risk group. However, the issue of whether RAI ablation
could replace pCND remains unclear and requires further
studies [8]. On the other hand, because of upstaging, it
is expected that more patients would require RAI ablation
and inevitably they would be subjected to potential draw-
backs from radiation, like salivary gland swelling, recurrent
sialoadenitis, dental caries, pulmonary fibrosis, nasolacrimal
outflow obstruction, and, more importantly, increased risk
of second primary malignancies on a long term [76–78].
A recent single-institution study found that cumulative
RAI activity = 3.0−8.9GBq was an independent risk factor
for the development of nonsynchronous second primary
malignancy after adjusting for tumor stage and period of
DTC diagnosis (relative risk = 2.38, P = 0.040) [78].
In terms of followup and long-term surveillance, since
pCND results in a higher rate of postsurgical-stimulated
athyroglobulinemia, the authors believe that pCND could
facilitate followup and ultrasound surveillance of the neck
compartments [5, 6, 8, 26]. This is particularly so if a cancer
cure is defined by having athyroglobulinemia [8].
7. Extent of pCND and its Patient Selection
While the debate over pCND in DTC rages on, it would
appear that the most rational approach would be to decide
whether to perform pCND based on patients’ risk stratifica-
tion or on novel prognostic factors such as BRAF mutations
with an aim of minimizing the overall surgical morbidity
rate.
8. Extent of Surgery
According to the revised ATA guideline, either unilateral or
bilateral paratracheal LN would be regarded as a formal
CND but either would still result in morbidity in inexperi-
enced hands. Since surgical morbidity is directly related to
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the extent of surgical dissection, a limited or unilateral
pCND might seem like a logical choice [8, 20, 79]. As
lymphatic spread of tumor cells tends to occur in a stepwise
fashion, from thyroid gland to ipsilateral central neck first,
to ipsilateral lateral neck, and later to contralateral central
neck, skip metastasis leaping central neck compartment
is uncommon [80]. Therefore, the ipsilateral central neck
compartment is the most common site for lymph node
metastasis. Ipsilateral central neck involvement occurs in up
to 69%, while contralateral central neck occurs in 10∼20%
[81–83]. Moo et al. analyzed a cohort of 116 patients with
papillary thyroid cancer undergoing thyroidectomy with
pCND and none of patients with tumor size ≤1 cm have
contralateral lymph node metastasis [16]. Other studies have
shown that bilateral central nodal metastasis is correlated
with tumor multifocality, presence of metastasis in all lateral
neck levels and ipsilateral involvement of central neck dissec-
tion [84, 85]. Compared with unilateral (ipsilateral) pCND,
bilateral pCND was associated with higher rate of temporary
hypoparathyroidism (20.5% versus 48.0%; P = 0.009),
(26.8% versus 48.3%; P = 0.021), while no significant diﬀer-
ence in rate of postablation athyroglobulinemia (64% versus
57.1%, P > 0.05) or recurrence (7.1% versus 8.6%, P > 0.05)
[86, 87]. In the authors’ opinion, if one has decided on per-
forming a pCND, an unilateral rather than a bilateral pCND
would appear to be the correct choice as it provides a balance
between achieving surgical completeness and avoiding signif-
icant surgical morbidity. On the other hand, for patients with
high risk factors such as multifocality or ipsilateral central
or lateral lymph node metastasis, bilateral pCND would
seem to be more appropriate given the higher incidence of
contralateral central lymph node involvement [84, 85].
Cervical thymus is occasionally removed in the central
neck dissection [29]. But thymectomy is associated with
increased risk of transient hypocalcaemia [20]. This is
because of extensive dissection leading to devascularization
of inferior parathyroid gland or unintentional removal
of inferior parathyroid located in thyrothymic ligament
or thymus (41%) [88]. Similar to paratracheal dissection,
bilateral cervical thymectomy results in higher rate of
temporary hypocalcaemia (35.5% versus 10.7%; P < 0.001),
while contralateral intrathymic lymph node metastasis is
rare. Therefore, unilateral cervical thymectomy would seem
appropriate [89].
9. Patient Selection
Large tumor size, extrathyroidal extension, and multifocality
are associated with increased risk of central neck lymph
node metastasis [90]. These tumors are more likely to
harbor metastasis in central neck compartment. On the
other hand, large tumor size, gross extrathyroidal extension
and adverse histological features and ipsilateral central neck
metastasis are also poor risk factors for recurrence [91]. On
selecting patients for pCND, these factors should therefore
be considered at the time of operation [91].
Sentinel lymph node dissection has been advocated in
management of breast and melanoma [92, 93], but its appli-
cation in DTC remains limited and underinvestigated. This
is because firstly a pCND can be performed using the same
neck incision as the thyroidectomy and the surgical morbid-
ity is still relatively low when compared to other lymph node
dissections (e.g., axillary or groin dissection). Nevertheless,
in theory, it is believed that lymphatic metastasis occurs
in stepwise manner, and, by removing the first draining
lymph node(s), it could predict the regional pathological
lymph node status. Some proponents suggested that it could
allow for more accurate staging, better patient selection to
undergo formal CND and RAI ablation, and identification
of sentinel lymph node outside central compartment [93].
Some authors commented that they encountered diﬃculties
with injecting or mapping label material into small nodule in
a peritumoral fashion, particularly when the tumor involved
the whole lobe. For tumors in a multinodular goiter, it is
also diﬃcult to identify the site for injection and injections
could lead to rupture of cystic lesion [94]. Early small single-
center studies reported a high false-negative rate for SLN
detection of up to 12 ∼ 22% with blue dye injection or
radio-isotope injection [95, 96]. And, more importantly,
performing sentinel lymph node biopsy did not seem to
reduce recurrence [97].
Nevertheless, a recent meta-analysis including 24 studies
on sentinel node biopsy for thyroid cancer showed promising
results. They found the overall false negative rate for blue
dye, radio-isotopes, and combined methods were 7.7, 16,
and 0 percent, respectively. The false negative in frozen
section of SLN was 12%, which is comparable to sentinel
lymph node biopsy examination for breast cancer. According
to the results, more than half of patients with clinically
negative lymph nodes could potentially avoid prophylactic
neck dissection [97].
In addition to lymph node metastasis, older age, extra-
thyroidal extension, aggressive histology subtype, distant
metastasis, and presence of BRAF mutation are associated
with higher recurrence [98–100]. Presence of BRAF muta-
tions is associated with higher risks in nodal involvement and
recurrence [99–101]. New technologies are now available to
test the BRAF status in FNA sample. Perhaps, by detecting
BRAF mutations preoperatively, surgeons would be able to
decide which patients should undergo pCND and total thy-
roidectomy and which should undergo total thyroidectomy
alone [102, 103]. However, further studies are required.
10. Difficulties and Biases with Conducting
Studies on pCND in DTC
Since there is no prospective randomized trial to evaluate
the eﬃcacy of pCND, evidence on pCND comes from case
series or retrospective cohort or analysis. The diﬃculty of
conducting a prospective study could be explained by its
indolent nature of DTC, as most patients live for more than
10 years [104] and recurrence may occur up to 20 years after
primary diagnosis [67, 105]. Perhaps, future studies could
evaluate the potential role of molecular markers such as
VEGF-C to predict lymph node recurrences [106]. Therefore,
evaluating survivals as endpoints might be diﬃcult and
unrealistic. The natural history of DTC would be for some
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patients to undergomultiple neck operations and that results
in a negative impact on quality of life. Therefore, assessing
the number of recurrences and surgical morbidity within
a cohort might be more realistic in patients with DTC.
However, a large number of cases following up over a long
period of time would be needed to detect a small diﬀerence
(i.e., power of the study). The second problem relates to the
indication for pCND as there is often individual surgeon’s
bias. Though recent studies have designated nature of pCND
as therapeutic or prophylactic in nature, the decision for
pCND was mostly at the discretion of the operating surgeon
[6, 8, 65]. Patients who underwent pCND were generally
more likely to have more risk factors such as larger tumor
size, extrathyroidal extension, and multifocality which might
have been easily detectable during operation [8, 65]. High-
risk patients are generally more likely to undergo pCND,
and this may attenuate the potential benefit of pCND.
Furthermore, disease status is upstaged in up to 30% of
patients undergoing pCND, and this in turn increases the
overall proportion of patients receiving RAI ablation [6, 8].
11. Conclusion
There is little good evidence to support the routine prac-
tice of pCND in patients with DTC undergoing a total
thyroidectomy. Although the recent revised ATA guideline
has clarified many inconsistencies and has recommended
the practice of pCND based on tumor risks and stages,
many issues and controversies surrounding the subject
of pCND in DTC remain. Nevertheless, in the recent
literature, there has been a trend toward lower recurrence
rate in those with pCND when compared to those without
pCND. However, this is subjected to biases and there is
always the concern of its applicability in the wider surgical
community, as the outcomes of pCND are volume-related.
An ipsilateral unilateral pCND would appear to provide a
good balance between achieving surgical completeness and
avoiding adding significant surgical morbidity if pCND was
indicated. Balancing the surgical morbidity and long-term
benefits as well as better patient selection (i.e., high tumor-
risk groups) to undergo pCND would be the keys. Further
studies on this controversial subject are much needed.
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